Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease.
CITATION STYLE
Livingstone, R., Boyle, J. G., & Petrie, J. R. (2017, September 1). A new perspective on metformin therapy in type 1 diabetes. Diabetologia. Springer Verlag. https://doi.org/10.1007/s00125-017-4364-6
Mendeley helps you to discover research relevant for your work.